ewsba.se
Genmab A/S (NASDAQ:GMAB) ranks among the most profitable biotech stocks to buy now. Wolfe Research began coverage of Genmab A/S (NASDAQ:GMAB) on March 26 with a price objective of $32 and an Outperform rating. In anticipation of clinical triggers anticipated in 2026, the firm sees the current price dip following a loss in a confirmatory DLBCL study as a purchasing opportunity.
According to the firm, Genmab’s Epkinly is expected to bring in $3.4 billion in peak sales, with the frontline trial EPCORE DLBCL-2 being the main value engine for the asset. Similarly, Rina-S could generate $2.5 billion in peak sales spanning many indications, with Wolfe anticipating findings from the RAINFOL-01 PROC this year.
Also, with regard to sales, Genmab A/S (NASDAQ:GMAB) reported that DARZALEX’s global net sales amounted to $3.964 billion in Q1 2026. The sales data include cancer treatment formulas administered intravenously and subcutaneously. Net sales in the US totaled $2.208 billion, with international markets generating $1.756 billion in revenue.
Genmab A/S (NASDAQ:GMAB) is a biotechnology company specializing in oncology, developing innovative antibody-based therapies for cancer treatment. Its late-stage pipeline includes promising programs like Rina‑S and EPKINLY.
While we acknowledge the potential of GMAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.